RUNX1 and metabolic dysfunction-associated steatohepatitis: Treatment with the immunonano-lipocarrier encapsulated siRNA results in a decrease in RUNX1 expression in LSECs and reduces the expression of adhesion molecules, causing decreased infiltration of myeloid and T cells in liver, and finally attenuating inflammation in NASH liver.